Biogen Historical Income Statement

BIIB Stock

USD 158.01 0.00 0.00%

Historical analysis of Biogen income statement accounts such as Interest Expense of 259.2 M, Selling General Administrative of 2.6 B or Total Revenue of 10.3 B can show how well Biogen Inc performed in making a profits. Evaluating Biogen income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Biogen's future profits or losses.

Cash Flow Balance Sheet Income Statement

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Biogen Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biogen Inc is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

About Biogen Income Statement Analysis

Biogen Inc Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Biogen shareholders. The income statement also shows Biogen investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Biogen Income Statement Chart

At present, Biogen's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 2.6 B, whereas Depreciation And Amortization is forecasted to decline to about 257.5 M.

Selling General Administrative Total Revenue Gross Profit Other Operating Expenses Reconciled Depreciation

Total Revenue

Total revenue comprises all receipts Biogen Inc generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Biogen Inc minus its cost of goods sold. It is profit before Biogen operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Biogen Inc. It is also known as Biogen overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Biogen's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Biogen Inc current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

	2021	2022	2023	2024 (projected)
Gross Profit	8.9B	7.9B	7.3B	3.9B
Total Revenue	11.0B	10.2B	9.8B	10.3B

Gross Profit Total Revenue

Biogen income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Extraordinary Items	Minority Interest	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Selling And Marketing Expenses	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.59	0.6	0.79	0.81	0.65	0.7	0.69	0.73	0.57	0.71	0.67	-0.09	0.57	0.72	0.69	0.06	0.5	0.52	-0.11	-0.15	0.33	0.32	-0.15	0.14	-0.16
Interest Expense	0.59		0.72	0.73	0.54	0.83	0.38	0.42	0.45	0.88	0.74	0.34	-0.44	0.33	0.23	0.63	0.47	0.4	0.28	0.15	0.13	0.41	-0.25	0.13	0.44	-0.66
Selling General Administrative	0.6	0.72		0.83	0.64	0.96	0.44	0.42	0.44	0.9	0.93	0.4	-0.29	0.45	0.13	0.74	0.27	0.28	0.34	0.16	-0.34	0.55	-0.42	0.19	0.42	-0.67
Total Revenue	0.79	0.73	0.83		0.92	0.87	0.83	0.82	0.84	0.75	0.92	0.81	-0.11	0.8	0.57	0.84	0.2	0.28	0.74	0.01	-0.17	0.66	0.04	-0.06	0.29	-0.39
Gross Profit	0.81	0.54	0.64	0.92		0.66	0.93	0.91	0.92	0.49	0.79	0.9	0.06	0.88	0.69	0.84	0.02	0.31	0.84	-0.18	-0.14	0.59	0.26	-0.34	0.01	-0.17
Other Operating Expenses	0.65	0.83	0.96	0.87	0.66		0.46	0.45	0.47	0.94	0.96	0.42	-0.28	0.45	0.19	0.81	0.41	0.3	0.36	0.24	-0.28	0.56	-0.36	0.22	0.51	-0.71
Operating Income	0.7	0.38	0.44	0.83	0.93	0.46		0.97	0.97	0.31	0.59	0.97	0.09	0.92	0.8	0.61	-0.1	0.11	0.91	-0.23	-0.03	0.57	0.46	-0.3	0.02	0.09
Ebit	0.69	0.42	0.42	0.82	0.91	0.45	0.97		1.0	0.32	0.57	0.99	0.19	0.94	0.82	0.62	-0.1	0.09	0.93	-0.09	0.09	0.52	0.49	-0.31	0.01	0.05
Ebitda	0.73	0.45	0.44	0.84	0.92	0.47	0.97	1.0		0.35	0.59	0.98	0.17	0.93	0.84	0.64	-0.08	0.13	0.92	-0.09	0.07	0.52	0.48	-0.31	0.02	0.03
Cost Of Revenue	0.57	0.88	0.9	0.75	0.49	0.94	0.31	0.32	0.35		0.82	0.29	-0.39	0.33	0.06	0.63	0.55	0.25	0.25	0.32	-0.15	0.4	-0.47	0.38	0.64	-0.78
Total Operating Expenses	0.71	0.74	0.93	0.92	0.79	0.96	0.59	0.57	0.59	0.82		0.56	-0.14	0.57	0.32	0.91	0.29	0.38	0.49	0.09	-0.34	0.64	-0.21	-0.01	0.3	-0.6
Income Before Tax	0.67	0.34	0.4	0.81	0.9	0.42	0.97	0.99	0.98	0.29	0.56		0.29	0.97	0.81	0.6	-0.07	0.07	0.95	-0.08	-0.02	0.48	0.49	-0.32	0.0	0.05
Total Other Income Expense Net	-0.09	-0.44	-0.29	-0.11	0.06	-0.28	0.09	0.19	0.17	-0.39	-0.14	0.29		0.32	0.19	0.08	-0.04	-0.2	0.36	0.33	-0.19	-0.28	0.39	-0.3	-0.26	0.11
Net Income	0.57	0.33	0.45	0.8	0.88	0.45	0.92	0.94	0.93	0.33	0.57	0.97	0.32		0.63	0.62	0.06	-0.01	0.99	-0.03	-0.05	0.49	0.3	-0.3	0.05	-0.08
Income Tax Expense	0.72	0.23	0.13	0.57	0.69	0.19	0.8	0.82	0.84	0.06	0.32	0.81	0.19	0.63		0.39	-0.38	0.23	0.63	-0.17	0.09	0.29	0.83	-0.33	-0.14	0.36
Research Development	0.69	0.63	0.74	0.84	0.84	0.81	0.61	0.62	0.64	0.63	0.91	0.6	0.08	0.62	0.39		0.27	0.39	0.57	0.08	-0.24	0.59	-0.06	-0.23	0.11	-0.52
Extraordinary Items	0.06	0.47	0.27	0.2	0.02	0.41	-0.1	-0.1	-0.08	0.55	0.29	-0.07	-0.04	0.06	-0.38	0.27		0.13	0.1	0.33	-0.07	0.02	-0.55	0.25	0.51	-0.76
Minority Interest	0.5	0.4	0.28	0.28	0.31	0.3	0.11	0.09	0.13	0.25	0.38	0.07	-0.2	-0.01	0.23	0.39	0.13		-0.02	-0.49	-0.26	0.13	0.05	-0.53	-0.39	-0.28
Net Income From Continuing Ops	0.52	0.28	0.34	0.74	0.84	0.36	0.91	0.93	0.92	0.25	0.49	0.95	0.36	0.99	0.63	0.57	0.1	-0.02		-0.07	0.01	0.47	0.35	-0.34	0.01	-0.04
Non Operating Income Net Other	-0.11	0.15	0.16	0.01	-0.18	0.24	-0.23	-0.09	-0.09	0.32	0.09	-0.08	0.33	-0.03	-0.17	0.08	0.33	-0.49	-0.07		0.01	-0.2	-0.23	0.68	0.68	-0.4
Non Recurring	-0.15	0.13	-0.34	-0.17	-0.14	-0.28	-0.03	0.09	0.07	-0.15	-0.34	-0.02	-0.19	-0.05	0.09	-0.24	-0.07	-0.26	0.01	0.01		0.15	0.16	-0.07	-0.1	0.26
Selling And Marketing Expenses	0.33	0.41	0.55	0.66	0.59	0.56	0.57	0.52	0.52	0.4	0.64	0.48	-0.28	0.49	0.29	0.59	0.02	0.13	0.47	-0.2	0.15		-0.09	-0.16	-0.01	-0.13
Tax Provision	0.32	-0.25	-0.42	0.04	0.26	-0.36	0.46	0.49	0.48	-0.47	-0.21	0.49	0.39	0.3	0.83	-0.06	-0.55	0.05	0.35	-0.23	0.16	-0.09		-0.41	-0.38	0.71
Interest Income	-0.15	0.13	0.19	-0.06	-0.34	0.22	-0.3	-0.31	-0.31	0.38	-0.01	-0.32	-0.3	-0.3	-0.33	-0.23	0.25	-0.53	-0.34	0.68	-0.07	-0.16	-0.41		0.89	-0.23
Net Interest Income	0.14	0.44	0.42	0.29	0.01	0.51	0.02	0.01	0.02	0.64	0.3	0.0	-0.26	0.05	-0.14	0.11	0.51	-0.39	0.01	0.68	-0.1	-0.01	-0.38	0.89		-0.45
Reconciled Depreciation	-0.16	-0.66	-0.67	-0.39	-0.17	-0.71	0.09	0.05	0.03	-0.78	-0.6	0.05	0.11	-0.08	0.36	-0.52	-0.76	-0.28	-0.04	-0.4	0.26	-0.13	0.71	-0.23	-0.45

Click cells to compare fundamentals

Biogen Account Relationship Matchups

Biogen income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	476.1M	457M	487.3M	518.7M	494.8M	257.5M
Interest Expense	187.4M	222.5M	253.6M	246.6M	246.9M	259.2M
Selling General Administrative	2.3B	2.4B	2.6B	2.3B	2.5B	2.6B
Total Revenue	14.4B	13.4B	11.0B	10.2B	9.8B	10.3B
Gross Profit	12.4B	11.6B	8.9B	7.9B	7.3B	3.9B
Other Operating Expenses	7.3B	9.0B	8.2B	7.3B	8.5B	9.0B
Operating Income	7.0B	4.6B	2.8B	2.3B	2.1B	1.6B
Ebit	7.0B	5.3B	2.0B	3.8B	1.9B	1.7B
Ebitda	7.5B	5.7B	2.5B	4.4B	2.4B	1.9B
Cost Of Revenue	2.0B	1.8B	2.1B	2.3B	2.5B	2.7B
Total Operating Expenses	5.4B	7.2B	6.1B	5.0B	5.2B	5.5B
Income Before Tax	7.1B	5.0B	1.7B	3.6B	1.3B	1.6B
Total Other Income Expense Net	83.3M	497.4M	(1.1B)	331.4M	(800.5M)	(760.5M)
Net Income	5.9B	4.0B	1.6B	3.0B	1.2B	1.2B
Income Tax Expense	1.2B	992.3M	52.5M	632.8M	135.3M	128.5M
Research Development	2.3B	4.0B	2.5B	2.2B	2.5B	1.4B
Net Income Applicable To Common Shares	5.9B	4.0B	1.6B	3.0B	3.5B	2.0B
Minority Interest	(4.1M)	59.9M	171.5M	85.3M	(400K)	(380K)
Net Income From Continuing Ops	6.0B	4.1B	1.7B	3.0B	1.2B	1.1B
Non Operating Income Net Other	3.9M	502.7M	(1.1B)	614.5M	706.7M	742.0M
Non Recurring	1.5M	75M	18M	131.1M	118.0M	99.1M
Selling And Marketing Expenses	79.2M	111.8M	98.7M	54.1M	71.4M	93.1M
Tax Provision	1.2B	992.3M	52.5M	632.8M	135.3M	128.5M
Interest Income	120M	42M	11M	89.3M	276.5M	290.3M
Net Interest Income	(67.4M)	(180.5M)	(242.6M)	(157.3M)	29.6M	31.1M
Reconciled Depreciation	680.6M	457.2M	487.7M	365.9M	494.8M	523.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:

How To Invest In Biogen

Details

Is Biogen Stock a good investment?

Details

What is Biogen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.02)

Earnings Share

11.07

Revenue Per Share

66.122

Quarterly Revenue Growth

(0.03)

Return On Assets

0.0499

The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Biogen Historical Income Statement

About Biogen Income Statement Analysis

Biogen Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Biogen income statement Correlations

Biogen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biogen income statement Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Income Before Tax	+ 0.99	Ebit
Net Income From Continuing Ops	+ 0.99	Net Income
Income Before Tax	+ 0.98	Ebitda
Ebit	+ 0.97	Operating Income
Ebitda	+ 0.97	Operating Income

Reconciled Depreciation	- 0.78	Cost Of Revenue
Reconciled Depreciation	- 0.76	Extraordinary Items
Reconciled Depreciation	- 0.71	Other Operating Expenses
Reconciled Depreciation	- 0.67	Selling General Administrative
Reconciled Depreciation	- 0.66	Interest Expense
Reconciled Depreciation	- 0.6	Total Operating Expenses